These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 20200560

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    Lou Z, Ren T, Peng X, Sun Y, Jiao G, Lu Q, Zhang S, Lu X, Guo W.
    J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
    [Abstract] [Full Text] [Related]

  • 5. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis.
    Saeki K, Kobayashi N, Inazawa Y, Zhang H, Nishitoh H, Ichijo H, Saeki K, Isemura M, Yuo A.
    Biochem J; 2002 Dec 15; 368(Pt 3):705-20. PubMed ID: 12206715
    [Abstract] [Full Text] [Related]

  • 6. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
    Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL.
    Cancer Lett; 2008 Jan 18; 259(1):82-98. PubMed ID: 18023967
    [Abstract] [Full Text] [Related]

  • 7. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.
    Anticancer Drugs; 2013 Jul 18; 24(6):609-16. PubMed ID: 23698252
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.
    Leukemia; 2009 Aug 18; 23(8):1507-14. PubMed ID: 19282831
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.
    Boronkai A, Bellyei S, Szigeti A, Pozsgai E, Bognar Z, Sumegi B, Gallyas F.
    Eur J Cell Biol; 2009 Dec 18; 88(12):753-63. PubMed ID: 19717209
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 18; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 16. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.
    Cancer Res; 2005 Jul 15; 65(14):6282-93. PubMed ID: 16024630
    [Abstract] [Full Text] [Related]

  • 17. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
    Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ.
    Cancer Res; 2004 Jul 01; 64(13):4394-9. PubMed ID: 15231645
    [Abstract] [Full Text] [Related]

  • 18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 19. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
    Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR.
    Oncogene; 2006 Oct 19; 25(49):6520-7. PubMed ID: 16702955
    [Abstract] [Full Text] [Related]

  • 20. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA, Khong T, Burns CJ, Spencer A.
    Leukemia; 2011 Dec 19; 25(12):1891-9. PubMed ID: 21788946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.